Research Study

A Phase 3, Randomized, Open-Label Study Evaluating Efficacy of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Subjects With Relapsed/Refractory Diffuse Large B Cell Lymphoma
Principal Investigator 
Kevin Song

Overview

Body Locations and Systems 
Blood
Disorders and Conditions 
Lymphoma
ClinicalTrials.gov# 
NCT03391466
Status 
Closed for Recruitment
Study Start/End 
Jul 16, 2018 to Jul 15, 2022
Locations 
Vancouver General Hospital
Name/Title 
Edward Wong, Research Assistant
Phone 
604-875-4111 ext.22966
Purpose of Study 

The purpose of this study is to evaluate whether axicabtagene ciloleucel therapy improves the clinical outcome compared with standard of care second-line therapy in patients with relapsed/refractory Diffuse Large B Cell Lymphoma.

Eligibility 

Visit ClinicalTrials.gov for more information.

Disclaimer 

Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific research studies only. If you have specific questions which require clinical expertise, please call your primary care physician.